Home
About
Overview
Sharing Data
ORCID
Help
History (16)
Fast model-based estimation of ancestry in unrelated individuals.
1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial.
Rapid image deconvolution and multiview fusion for optical microscopy.
Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture.
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?
See All 16 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? Thromb Res. 2020 10; 194:176-177.
View in:
PubMed
subject areas
Carcinoma, Non-Small-Cell Lung
Humans
Lung Neoplasms
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Receptor Protein-Tyrosine Kinases
authors with profiles
Marina Chiara Garassino